Recent Updates
Recently added Catalysts
NVCR Negative Sentiment Score: 25/100

NOVOCURE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against NovoCure Limited - NVCR

Key Takeaway: Kahn Swick & Foti, led by former Louisiana Attorney General Charles C. Foti, Jr., is reminding investors of the lead plaintiff deadline for a class action lawsuit against NovoCure Limited, stemming from allegations of not disclosing material information during a specified Class Period. Investors who purchased shares between January 5 to June 5, 2023, have until August 18, 2023, to file applications. Despite the company reporting positive results from a Phase 3 clinical trial, stock prices fell significantly due to concerns surrounding the therapy's application in non-small cell lung cancer treatment.

Market Sentiment Analysis

POSITIVE FACTORS

  • Kahn Swick & Foti reminds investors of their legal rights.
  • Positive results announced from the Phase 3 LUNAR clinical trial.

CONCERNS & RISKS

  • NovoCure is facing a securities class action lawsuit.
  • Company's stock fell 43.04% following the trial results.

Full Press Release Details

NEW ORLEANS, July 25, 2023 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 18, 2023 to file lead plaintiff applications in a securities class action lawsuit against NovoCure Limited (NasdaqGS: NVCR), if they purchased the Company’s securities between January 5, 2023 to June 5, 2023, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
If you purchased securities of NovoCure and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-nvcr/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by August 18, 2023.
NovoCure and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On June 6, 2023, the Company announced “positive results” from the Phase 3 LUNAR clinical trial evaluating the use of its Tumor Treating Fields therapy together with standard therapies for the treatment of non-small cell lung cancer; however, despite some positive aspects to the news, analysts noted that the therapy was tested in patients who worsened following chemotherapy, which is no longer the standard of care in lung cancer, and that most patients first receive immune checkpoint inhibitors.
On this news, shares of NovoCure fell $35.51 per share, or 43.04%, to close at $47.00 per share on June 6, 2023.
The case is Bazzelle v. NovoCure Limited, et al., No. 23-cv-5146.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, California, Louisiana and New Jersey.
To learn more about KSF, you may visit http://ksfcounsel.com/.
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
1100 Poydras St., Suite 960
New Orleans, LA 70163

Tags

Frequently Asked Questions

What is the deadline for filing a lead plaintiff application?

The deadline to file a lead plaintiff application is August 18, 2023.

What was the price drop for NovoCure shares on June 6, 2023?

NovoCure shares fell by $35.51, or 43.04%, closing at $47.00.

What was the phase of the clinical trial announced by NovoCure?

NovoCure announced results from the Phase 3 LUNAR clinical trial.

Who is the managing partner at Kahn Swick & Foti, LLC?

Lewis Kahn is the Managing Partner at Kahn Swick & Foti, LLC.

Which court is handling the NovoCure class action lawsuit?

The case is pending in the United States District Court for the Southern District of New York.

Last updated: Jul 26, 2023